Immunic Will Develop IMU-856, Promising IBD Therapy
News
Immunic earned the exclusive rights to develop a group of innovative disease-modifying therapies, now renamed IMU-856, for inflammatory bowel disease (IBD). IMU-856, originally developed by Daiichi Sankyo, is an oral small ... Read more